DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2018年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3555

Title: Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis.
Other Titles: スルフォラファンの肝癌発育抑制効果および血管新生抑制効果に関する基礎的検討
Authors: Sato, Shinya
Moriya, Kei
Furukawa, Masanori
Saikawa, Soichiro
Namisaki, Tadashi
Kitade, Mitsuteru
Kawaratani, Hideto
Kaji, Kosuke
Takaya, Hiroaki
Shimozato, Naotaka
Sawada, Yasuhiko
Seki, Kenichiro
Kitagawa, Kou
Akahane, Takemi
Mitoro, Akira
Okura, Yasushi
Yoshiji, Hitoshi
Yamao, Junichi
Keywords: Sulforaphane
Liver cancer
Issue Date: Dec-2018
Publisher: iMedPub LTD
Citation: Archives in cancer research Vol.6 No.4 Article No.23 (2018 Dec)
Abstract: Sulforaphane (SFN) exhibits inhibitory effects in different types of cancers. However, its inhibitory effect on liver cancer remains unknown. This study aimed to determine the therapeutic potential of SFN for the treatment of liver cancer and explore the functional mechanisms underlying the inhibitory effects of SFN. Water-Soluble Tetrazolium salt (WST-1) assay was performed to assess the in vitro effect of SFN on cell proliferation in the human liver cancer cell lines, HepG2 and Huh-7. The mRNA levels of Nrf2 target genes and cell cycle-related genes were determined using quantitative RT-PCR. For assessing the inhibitory effect of SFN in vivo, we injected immortalized liver cancer cells into BALB/c nude mice as a xenograft model. SFN was orally administrated daily after tumor inoculation and continued for thirty-five days until their sacrifices. Nrf2 activation, induced by SFN, was confirmed by mRNA upregulation of HO-1, MRP2, and NQO1 in both the cell lines. Significant inhibition of liver cancer cell proliferation by SFN was shown in vitro in a dose-dependent manner by the downregulation of CCND1, CCNB1, CDK1 and CDK2. In in vivo studies, the administration of SFN significantly reduced the subcutaneous tumor burdens at the end of experiments by suppressing tumor cell proliferation, confirmed by Ki67 immunohistochemical analysis. The mRNA levels of CCND1, CCNB1, CDK1 and CDK2 were also decreased in these SFNtreated xenograft tumors. Moreover, CD34 immunostaining elucidated that the intratumoral neovascularization was markedly attenuated in the SFN-treated xenograft tumors. SFN exerts inhibitory effect on human liver cancer cells with antiangiogenic activity. The earlier version of this study was presented at the meeting of AASLD Liver Learning on Oct 2017.
Description: 博士(医学)・甲第707号・平成31年3月15日
© The Author(s) 2018 Under License of Creative Commons Attribution 3.0 License https://creativecommons.org/licenses/by/3.0/
URI: http://hdl.handle.net/10564/3555
ISSN: 22546081
Academic Degrees and number: 24601A707
Degree-granting date: 2019-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2018年度

Files in This Item:

File Description SizeFormat
01甲707本文の要旨.pdf甲707本文の要旨1.95 MBAdobe PDFView/Open
02甲707審査要旨.pdf甲707審査要旨2.1 MBAdobe PDFView/Open
03甲707本文.pdf甲707本文670.08 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback